Articles tagged with Gliomas
Researchers discovered how ATRX mutations reprogram gene regulation architecture to fuel glioma growth and progression. Targeting genes downstream of ATRX slowed cancer progression in preclinical models.
A new study reveals that nitrosylcobalamin, a vitamin B12 analog, selectively crosses the blood-brain barrier and targets glioblastoma tissue, demonstrating broad antitumor activity. The therapy also shows synergistic activity with existing treatments, offering a promising new strategy for treating this deadly brain cancer.
A study found that HSP90B1 upregulates in gliomas and correlates with poor prognosis and tumor malignancy. It enhances tumor cell proliferation, migration, and invasion while protecting cells from radiotherapy-induced apoptosis by modulating DNA damage repair factors.
Pediatric low-grade gliomas require distinct treatment strategies, with a focus on molecular diagnosis and age-appropriate treatment. The new Chinese guidelines cover imaging, pathology, surgery, radiotherapy, and systemic therapy, aiming to maximize tumor control while protecting neurodevelopment.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
A new review analyzes how glioma classification research has evolved across clinical, molecular, and social domains. The study highlights the prominent role of DNA methylation profiling and advanced imaging techniques in molecular biomarker-based classification models, while finding social factors to be relatively scarce.
A comprehensive review of BNCT suggests it can precisely target and destroy cancer cells while sparing healthy tissue. The therapy has shown promising results in extending overall survival and improving quality of life for patients with various types of malignant tumors.
This study reclassified patients according to modern WHO Classification criteria, revealing molecular subtyping limitations, pathway co-activation patterns, and strong anatomical-molecular correlations. IDH1/2 mutations and TERT promoter mutations played key roles in determining prognosis.
A new study by Mass General Brigham highlights the efficacy of proton therapy in achieving excellent tumor control rates while minimizing side effects compared to traditional radiotherapy. Proton therapy limits radiation exposure to healthy tissue, potentially preserving cognition and hormone function.
Researchers have identified three unique subtypes of mismatch repair deficient high-grade gliomas, providing a clearer understanding of their development and behavior. The findings are helping guide more precise therapies and offer hope for a potential vaccine to target cancer cells earlier.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
A study of 101 glioma cases reveals that one-third of patients develop permanent paralysis after surgery. High tumor grade, pre-operative motor deficits, and larger tumor volume are key predictors. The work underscores the importance of careful surgical planning to maximize survival while safeguarding motor function.
Research highlights the role of ATAD2 in promoting glioma progression by co-activating PDK1 with E2F1, leading to poorer prognoses in patients. A personalized prognostic nomogram using CTARS has been developed for predicting clinical outcomes.
Researchers have discovered that ATAD2 promotes glioma progression by working with E2F1 to activate PDK1. The study also found that high levels of ATAD2 are associated with poorer outcomes in glioma patients.
Researchers found that lower LRIG1 expression is linked to more aggressive gliomas, a type of brain tumor. The study suggests that LRIG1 could serve as a useful marker for tumor severity and potentially as a target for future therapies.
The study identified two major factors that improve survival for children with IHG: achieving a complete surgical resection and cancer-directed adjuvant treatment. Early surgery in infants was fraught with risks of bleeding and early oncologic death, highlighting the need for strategies to minimize surgical morbidity.
Researchers identified a key metric, acoustic emission dose, to adjust ultrasound power and open the blood-brain barrier for delivering drugs in patients with high-grade gliomas. This allows for reliable treatment of brain cancer by bypassing the protective blood-brain barrier.
Pediatric high-grade glioma tumors have unique genetic patterns that can be targeted by immunotherapy. Researchers identified a specific protein structure, NRCAM, that is essential for cancer cell migration and invasion, making it an attractive target for new treatments.
Gene coexpression analysis reveals optimal markers of cell types and states, providing opportunities for developing novel biomarkers and targeted treatment strategies for glioma patients. Dr. Oldham's work tackles the reproducibility crisis in science, emphasizing data metadata standardization.
Researchers at Mayo Clinic have identified a potential new way to monitor the progression of high-grade gliomas by developing a personalized blood test tailored to each patient's tumor DNA. The study suggests that this approach may provide a clearer picture of disease progression and enable clinicians to make more informed treatment de...
A new AI tool has been developed to predict the relapse of pediatric brain cancer with high accuracy, using temporal learning algorithms to analyze sequential brain scans. The tool achieved an accuracy of 75-89% in predicting recurrence, outperforming predictions based on single images.
Scientists at St. Jude Children's Research Hospital discovered FOXR2 activation in multiple pediatric CNS tumor types, including high-grade gliomas and pineoblastomas, with significantly different clinical outcomes. The study highlights the importance of combining molecular findings with other diagnostic approaches to improve treatment...
A recent study reveals that high-mobility group nucleosomal-binding domain 2 (HMGN2) plays a crucial role in glioma progression and serves as a potential biomarker for predicting prognosis. HMGN2 regulates cell cycle progression by binding to histones, enhancing transcriptional activity of proliferation-related genes such as CDC20.
Recent research reveals that avapritinib, a PDGFRA inhibitor, demonstrates potent activity against pediatric high-grade glioma tumors with PDGFRA alterations. Clinical trials in patients showed an initial clinical response and improved survival rates, suggesting the potential for avapritinib as a therapeutic option.
Researchers identified 11 cuproptosis-related genes and classified IDH1-mutant gliomas into two subtypes with distinct clinical outcomes. A risk model using FDX1/SLC31A1-based features demonstrated superior prognostic performance, providing insights for chemotherapy selection and treatment resistance.
Researchers identified PDGFRA as a promising therapeutic target for pediatric high-grade gliomas. Inhibition of the PDGFRA signaling pathway leads to tumor cell death and has shown potential in laboratory and animal models, as well as initial clinical experience with avapritinib therapy.
Researchers found that avapritinib decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma. The drug targets the PDGFRA gene, which is commonly mutated in this type of cancer.
A new study reveals that firefighters are more likely to have a specific type of brain tumor with gene mutations linked to chemical exposure. The research found that firefighters were more likely to have the mutational signature associated with haloalkane exposure, especially those who worked for many years.
A new study by Mass General Brigham researchers has found a link between genetic mutations and toxin exposure in firefighters' brain tumors. The study identified a unique pattern of genetic mutations, known as a mutational signature, in many firefighter samples, especially those who had spent more years firefighting.
A Yale University study found an association between firefighters' exposure to chemicals and the development of glioma tumors with specific genetic patterns, previously linked to haloalkane exposure. The research suggests environmental agents may contribute to glioma risk, highlighting the need for preventive measures.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
Researchers combine radiation with a plant-derived compound to combat glioblastoma, forcing cancer cells into a dormant state. The approach significantly slows tumor growth and improves survival in mice models, offering a potential new avenue for combating this deadly form of brain cancer.
Researchers at Broad Institute of MIT and Harvard have identified four coordinated gene expression programs in immune cells from glioma tumors that can lead to immunotherapy resistance. The study found two programs that could be targeted to improve patient response to immunotherapies, including one that may reduce the effectiveness of ...
A new large-scale study published in Menopause found no significant association between hormone therapy use and risk of glioma, a common brain cancer. Women are still six times more likely to develop gliomas than men.
A randomized phase 3 trial found that adding temozolomide to radiation therapy improves long-term survival for adult patients with low-grade gliomas. The 10-year survival rate was 70% with combined treatment, compared to 47% with radiation alone.
Researchers developed an AI-powered model called FastGlioma that can detect residual tumor tissue with high accuracy in 10 seconds. The technology outperformed conventional methods, reducing the risk of missed tumors by nearly 75%. This innovation could change the field of neurosurgery and minimize reliance on radiographic imaging.
Researchers evaluated the efficacy and safety of using Zika virus for treating CNS tumors, finding that it reduces cell viability, inhibits growth, and decreases Bcl2 expression, potentially enhancing chemotherapy and radiotherapy effects. This ultimately led to significant tumor remission and improved long-term survival through an enh...
A new study reveals that a third of glioma cells, a type of brain tumor, fire electrical impulses. These hybrid cells combine features of neurons and glia, challenging the long-held notion that only neurons generate electric signals in the brain.
Researchers at Dana-Farber Cancer Institute have discovered that a specific subtype of pediatric high-grade glioma responds well to CDK4/6 inhibitors. Treatment with ribociclib slowed tumor growth and extended patient survival for 18 months, offering new hope for this devastating form of brain cancer.
Researchers at WEHI have identified a promising new two-in-one treatment that targets and destroys glioma cells while strengthening the immune system to prevent future tumour growth. CAR T cell therapy, using a specific immunotherapy targeting EphA3, has shown effective elimination of glioma cells and long-lasting immunity.
A new blood-based assay has been developed to detect IDH1.R132H-mutant gliomas with a high sensitivity of 75.0% and specificity of 88.7%. This minimally invasive test can monitor disease progression and response to treatment without the need for a biopsy.
The study provides a detailed analysis of high-grade glioma molecular characteristics, revealing shifts in gene expression and tumour microenvironment. Longitudinal samples revealed unique opportunities to observe tumour evolution, shedding light on genetic and epigenetic events associated with recurrent disease.
Researchers at the University of Michigan Health Rogel Cancer Center discovered that pediatric DIPG tumors have a distinct metabolic pathway that allows them to evade treatment. By inhibiting this pathway, radiation therapy became effective in killing cancer cells.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have found a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas. Adding an immune-boosting agent, poly-ICLC, to a personalized dendritic cell vaccine improves the immune response and activity of T cells in patients.
A study by researchers at Washington University School of Medicine has found that a drug used to treat epilepsy can prevent brain tumor formation and growth in mice with neurofibromatosis type 1 (NF1). The drug, lamotrigine, was shown to be effective at lower doses than those used for epilepsy, and its effects were lasting. The finding...
A new model of glioblastoma's key feature, oncostreams, could help scientists understand how to develop new treatments for this aggressive brain cancer. The model, developed by a team at the University of Michigan, identifies a potential inhibitor that appears to dismantle oncostreams, leading to better survival in mouse models.
Recent advances in permeating the brain-blood barrier hold promise for using radiopharmaceuticals to treat brain tumors. Theranostic approaches show encouraging preliminary results, particularly for meningiomas and pediatric brain tumors.
Researchers have uncovered the molecular and ultrastructural features of BCAS1+ cells in diffuse gliomas, highlighting their proliferative capacity and distribution. The study provides a comprehensive characterization of the BCAS1+ cell population within diffuse gliomas, shedding light on its role in tumor malignancy.
Researchers have identified regional biological signatures in invasive brain tumor margins of high-grade glioma, which could lead to improved diagnosis, prognosis, and treatment. Advanced MRI techniques may help distinguish between the genetic and molecular alterations, providing insights into resistance to treatment.
Researchers found XRCC1 to have both positive and negative correlations with prognosis across different tumors. The study also revealed associations between XRCC1 expression and DNA methylation patterns, TMB, MSI, immune cell infiltration levels, and immune checkpoint gene expression.
A new cancer GPS method uses a water-soluble, luminescent europium complex to evaluate the malignancy grade of model glioma tumor cells without causing harm. The method measures changes in the lifetime of the complex's red-light emission, revealing differences in tumor activity and growth processes between different malignancy grades.
Researchers aim to improve glioma treatment with direct light therapy that targets cancer cells without harming healthy ones. The project will investigate the efficacy and safety of this approach, potentially leading to improved treatment outcomes.
Researchers discovered that a little-understood synapse in the brain plays a pivotal role in producing myelin, the protective sheath around nerve cells. This finding could lead to new therapies for multiple sclerosis, neurodegenerative conditions and brain cancer.
A new framework has been established for standardized imaging of diffuse gliomas using amino acid PET, enabling the evaluation of treatment success and improving therapies. The RANO group has developed criteria that enable reliable imaging of tumor activity and extent.
A Phase II clinical trial has shown a clear clinical benefit of combining Dabrafenib and Trametinib in treating BRAF mutated low-grade paediatric gliomas. The combination therapy improved overall response rate by over four-fold and increased median progression-free survival.
A research team led by HKUST developed an AI-powered model to predict glioma patients' prognosis and identify early predictors of tumor evolution under therapy. The model, CELLO2, uses genomic and transcriptomic data from 544 glioma patients to accurately predict treatment-induced hypermutation and grade progression.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
A new set of criteria, RANO 2.0, has been proposed to improve the assessment of progression in glioma patients and accelerate the development of new treatments for brain tumors.